Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Therapy Focus
Snapshot: 2026-09-04
Bispecific & Multispecific Antibodies Active Trials in China
As of 2026-09-04, there are 17 active clinical trials investigating Bispecific & Multispecific Antibodies for multiple myeloma across 30 provinces and 174 study centers in China. Bispecific antibodies redirect T cells to attack myeloma cells by concurrently binding CD3 and tumor surface targets (BCMA, GPRC5D, FcRH5) as off-the-shelf immunotherapies.
Active Trials
17
Provinces
30
Centers
174
Active Studies (17)
Population synthesized by CMDNShowing 1 published English records of 17 registry trials.
Phase ICTR20260125
RecruitingA Phase I, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HL17 in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Recombinant anti-BCMA and CD3 bispecific antibody injection
Study Sites: PKU Healthcare Luzhong Hospital